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Besides the role that normal stem cells play in organogenesis, cancer stem cells are 
thought to be crucial for tumorigenesis. Most current research on human tumors is 
focused on the molecular and cellular analysis of the bulk tumor mass. However, 
evidence in leukemia and, more recently, in solid tumors suggests that the tumor cell 
population is heterogeneous. During the last years, several groups have described the 
existence of a cancer stem cell population in different brain tumors. These neural cancer 
stem cells (NCSC) can be isolated by cell sorting of dissociated suspensions of tumor 
cells for the neural stem cell marker CD133. These CD133+ cells, which also express 
nestin, an intermediate filament that is another neural stem cell marker, represent a 
minority fraction of the entire brain tumor population. The stem-like cancer cells appear 
to be solely responsible for propagating the disease in laboratory models. A promising 
new approach to treat glioblastoma proposes targeting cancer stem cells. Here, we 
summarize progress in delineating NCSC and the implications of the discovery of this 






The cancer stem cell hypothesis proposes that cancers derive from a small 
fraction of cancer cells that constitute a reservoir of self-sustained cells with the 
exclusive ability to self-renew and maintain the tumor.  There is increasing evidence 
that malignant tumors, such as leukemias, breast cancer and brain cancers, contain cells 
that maintain the characteristics of tissue-specific stem cells. These stem-like tumor 
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cells are bestowed with dysregulated potential for self-renewal, excessive proliferation, 
and aberrant differentiation into a heterogeneous progeny of cancer cells culminating in 
the intra-tumor heterogeneity. Rapidly accumulating evidence from various laboratories 
has shown that in several forms of human cancer, only a minority subpopulation of 
cancer cells are able to form new tumors when transplanted into immunodeficient mice. 
The population of cells selectively endowed with tumorigenic capacity can be purified 
from whole tumor tissues by virtue of a surface marker expression profile, and is 
currently defined as the “cancer stem cell” population. Cancer stem cells have been 
identified from various solid tumors including breast (CD44+ and CD24–/low), colorectal 
(CD133+), ependymoma (CD133+, Nestin+ and BLBP+) and glioblastoma (CD133+) 
(Al-Hajj et al., 2003; Singh et al., 2004; Taylor et al., 2005; O'Brien et al., 2007). 
Currently, an intense debate is ongoing as to whether cancer stem cells originate from 
adult stem cells or from mature, committed progenitors and/or even terminally 
differentiated cells that have abnormally acquired self-renewal capacity(Singh et al., 
2004). It is also suggested that niche cells could also be a primary target for the 
carcinogenic insult to adult stem cells, thereby inciting a tumorigenic response (Tlsty 
and Hein, 2001). Thus, the molecular mechanisms underlying the genesis of cancer 
stem cells are still obscure and identification of unique cell surface markers for cancer 
stem cell isolation could provide new tools to address these questions and allow for 
further molecular and functional characterizations.  
 
High-grade gliomas, which include glioblastoma (GBM) and anaplastic 
astrocytoma, are among the most common intrinsic brain tumors in adults and are 
nearly uniformly fatal. While there has been progress in understanding the molecular 
genetics of these tumors(Kitange et al., 2003), the cell types of origin are still uncertain, 
and the molecular determinants of disease aggressiveness are not well understood. A 
better understanding of the cellular origin and molecular pathogenesis of these tumors 
may identify new targets for treatment of these neoplasms. Until recently, GBMs were 
presumed to arise from glial cells residing within the brain parenchyma However, recent 
evidence suggests that neural stem cells can be an alternate cellular origin of gliomas 
(Singh et al., 2003; Caussinus and Gonzalez, 2005; Zhu et al., 2005). In fact, recent 
evidence demonstrates that neural stem cells can give rise to neoplasms that 
recapitulates the histopathological hallmarks of human gliomas (Bachoo et al., 2002; 
Uhrbom et al., 2002).   
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Adult neural stem cells are cells in the adult nervous system that can self-renew 
and differentiate into all types of neural cells, including neurons, astrocytes, and 
oligodendrocytes (Gage, 2000). In the adult human forebrain, the majority of neurons 
are born by the early postnatal period, but it has been demonstrated that neurons 
continue to arise in two niches of the adult brain, the subventricular zone (SVZ) of the 
lateral ventricle and in the subgranular zone (SGZ) of the dentate gyrus (Luskin et al., 
1997; Gage et al., 1998). In the hippocampus, granule neurons arise in the subgranular 
zone of the dentate gyrus. Progenitor cells in the SVZ migrate to the olfactory bulb 
(OB) through the rostral migratory stream (RMS) where they differentiate into granule 
and periglomerular neurons of the OB (Figure 1). Both cell-extrinsic and cell-intrinsic 
factors have been shown to influence the maintenance and regulation of the neurogenic 
system in vivo (Ostenfeld and Svendsen, 2003). A number of factors, including the 
brain-derived neurotrophic factor, insulin-like growth factor-1, epidermal growth factor 
(EGF) and the basic fibroblast growth factor (bFGF), have been shown to affect the 
proliferation and differentiation of precursor cell populations (Bartlett et al., 1995; Johe 
et al., 1996). This population of neural stem cells has distinct features such as the 
capacity of self-renewing, multipotency, asymmetric division, and express 
characteristics markers such as nestin, a cystoskeletal protein, CD133, a cell surface 
marker of normal neural ítem cells,  and Notch. The demonstration that the adult human 
brain contains an abundant source of neural stem cells and that GBMs contain 
tumorigenic neural stem-like cells indicate that neural stem cells are a plausible origin 
of human gliomas and have given rise to speculation that more effective therapies will 
result from approaches aimed at targeting the stem cell-like component of GBM 
(Ignatova et al., 2002; Berger et al., 2004; Oliver and Wechsler-Reya, 2004; Fomchenko 
and Holland, 2005). Glioblastoma tumor stem cells possess the capacity to self-renewal 
leading to daughter cells with the same predisposition for replication as the parental 
cells, and the capacity to recapitulate the generation of a growing tumor (Clarke, 2004). 
These capacities have been shown for CD133+ cells isolated from glioblastoma (Galli et 
al., 2004). A small number of CD133+ cells are sufficient for the formation of 
glioblastoma in immunodeficient mice. The resulting primary xenograpgh consisting of 
a minority of CD133+ cells and a majority of CD133- cells is a phenocopy of the 
patient’s tumor (Singh et al., 2004). 
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In addition to possessing the fundamental stem cell properties of self-renewal 
and multi-potency, glioblastoma stem cells share other characteristics with neural stem 
cells. They were first isolated from tumors by virtue of the expression of CD133 that 
marks neural stem and progenitor cells (Singh et al., 2004). The similarities in gene 
expression suggest that common cell signaling systems might operate in normal and 
malignant neural stem cells. These phenotypic and functional similarities suggest that 
glioblastoma stem cells might arise from normal neural stem cells that retain self-
renewal properties but acquire mutations necessary for tumorigenicity. Indeed, deletion 
of Nf1 and Trp53 from neural stem cells in mice initiates gliomagenesis in the 
subventricular zone (SVZ), where neural stem cells reside (Zhu et al., 2005). However, 
whether human glioblastoma stem cells arise from mutated neural stem cells or a more 
mature cell type that acquires self-renewal capacity remains to be determined. 
 
The stem cell niche 
  
It has been long recognized that normal stem cells of various tissues are tightly 
regulated by the immediate microenvironment or stem cell niche(Moore and 
Lemischka, 2006). Consequently, an important question is whether glioblastoma stem 
cells also depend on cues from the environment for survival. Stem cell niches are not 
merely repositories for stem cells, but are complex dynamic entities that actively control 
stem cell function (Scadden, 2006) regulating stem cell-renewal and fate. This 
microenvironment of stem cells is known to help maintain the cells in a “quiescent” 
state and preserve their potential to proliferate and differentiate (Fuchs et al., 2004; 
Ailles and Weissman, 2007). Direct genetic alterations or dysregulated crosstalk 
between signaling pathways of the CSCs and the cells of their microenvironment have 
been implicated as important determinants of functional tumor microenvironment 
preceding cancer development (Moinfar et al., 2000; Lopez-Otin and Matrisian, 2007). 
As commented in the Introduction, studies conducted during the last years have 
identified stem cells with regenerative capacity in the subventricular zone and the 
subgranular zone of the dentate gyrus. The central structural element of the neural stem 
cell niche is provided by capillaries within these zones. This organization places the 
stem cells in close proximity to endothelial and other vascular cells, facilitating 
communication among these cell types. The existence of niches extends to tumor cells 
as well. The tumor microenvironment, composed of nonepithelial stromal cells 
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increasingly is shown to be essential for tumor growth (Figure 2) (Kenny et al., 2007). 
Neural cancer stem cells have been shown to lie within a vascular microenvironment. In 
this regard, Calabrese et al recently provided convincing evidence that stem cells from 
various brain tumors, including glioblastoma, are indeed maintained within vascular 
niches that mimic the neural stem cell niche (Calabrese et al., 2007). Using co-
immunofluorescence and multi-photon laser scanning microscopy, they showed first 
that CD133+/Nestin+ tumor cells are closely associated with vasculature. Furthermore, 
increasing the number of endothelial cells and blood vessels in xenografts augmented 
the NCSC population and the rate of tumor growth. Clinical trials of the anti-angiogenic 
drug bevacizumab (Vredenburgh et al., 2007) have demonstrated a potent anti-tumor 
effect in patients with glioblastoma. This effect could be the result of a depletion of the 
tumor blood supply. However, the presence of a glioblastoma stem cell niche would 
imply that this drug might also function to disrupt stem cell maintenance. In this regard, 
Calabrese and colleagues showed that treating glioblastoma-bearing mice with 
bevacizumab depleted tumor blood vessels and caused a significant reduction both in 
the NCSC population and tumor growth rate. Interestingly, this treatment did not alter 
the proliferation or survival of most of the cells in the tumor, suggesting that the drug 
was specifically acting on the cancer stem cells. The notion that cancer stem cells exist 
in aberrant cell niches is an attractive one. A recent study of human gliomas suggests 
that bone morphogenic proteins, which are niche-derived regulators of neural stem cell 
fate might also regulate the differentiation status of cancer stem cells (Piccirillo et al., 
2006). Therefore, the tumor microenvironment offers a novel approach to treatment 
through the targeting of cells inside the tumor niche.  
 
Identifying Glioblastoma Stem Cells 
 
Correctly identifying stem cells in vivo remains the biggest obstacle to progress 
in understanding stem cell biology. The identification of reliable markers will allow 
prospective isolation and characterization of a pure population of CSCs, not just a 
population of cells containing CSCs. Normal stem cells and their neighboring cells 
within tissues can rarely be located by histological methods. Some properties that have 
been widely assumed to mark stem cells, such as preferential bromodeoxyuridine 
(BrdU) label retention (caused by an expected tendency of stem cells to divide more 
slowly than many of their progeny) have frequently proven to be unreliable without the 
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use of other markers (Crittenden et al., 2006; Barker et al., 2007; Kiel et al., 2007). The 
“side population” (SP) is defined by Hoechst dye exclusion in flow cytometry and has 
been commonly used as one of the methods of enriching for cancer stem cells in 
glioblastomas (Kondo et al., 2004) and also in other types of tumor cells. Goodell et al. 
have demonstrated that the exclusion of Hoechst 33342 dye by SP cells is a dynamic 
process involving the multidrug resistance transporter 1 (MDR1), a member of the ABC 
transporter transmembrane proteins (Goodell et al., 1996; Hirschmann-Jax et al., 2004). 
However, MDR1 cannot be taken as a single marker to identify and isolate SP cells, and 
additional transporters should be analyzed.  
 
Much work has been carried out on brain tumor stem cells enriched by the cell 
surface marker, CD133. It is unclear at this time whether the SP overlaps with the 
CD133 population, but both markers have been shown to be highly enriched in 
neurosphere-forming capacity (Yuan et al., 2004; Beier et al., 2007), one of the defining 
characteristics of neural stem cells and progenitors (Figure 3).  Recently, several groups 
have isolated NCSC from glioblastomas (Singh et al., 2003). They cultured dissociated 
tumor samples and expanded the cells on a defined, serum-free medium containing 
fibroblast growth factor and epidermal growth factor. These cells form floating 
aggregates (neurospheres) just as normal neural stem cells do in the same conditions. 
These neurospheres retain the self-renewing capacity and expressed neural stem cell 
markers, such as nestin, CD133, and Notch. Such aggregates, highly enriched in long-
term, self-renewing multipotent cells in vitro, formed malignant tumors when 
transplanted in vivo in immunodeficient mice. These findings indicate that 
glioblastomas contain cancer initiating neural stem-like cells, which can be identified by 
their staining with CD133 (Singh et al., 2003; Singh et al., 2004). Furthermore, it has 
been recently shown that CD133 expression correlates with patient survival in gliomas, 
lending support to the current cancer stem cell hypothesis (Zeppernick et al., 2008). 
These authors have found, using a large panel of human glioma samples, frequencies of 
CD133+ cells to increase with tumor grade, with many glioblastomas containing > 25% 
positive cells. In contrast, tissue sections of many WHO grade tumors were devoid of 
immunoreactive cells, probably indicating a low frequency of CSCs in these less 
malignant tumors. These findings provide strong valuable evidence for the CSC 




Another important trait of brain tumor stem cells is the signaling trough Notch 
receptor. Notch signaling is strongly activated in primary human gliomas and in several 
glioma cell lines (Pahlman et al., 2004) where its depletion reduces tumor proliferation 
(Purow et al., 2005). Moreover, transfection of downstream mediators of the Notch 
pathway results in an increase in the growth and sphere formation of human glioma 
CD133+ cells, indicating that Notch signaling is essential for the maintenance and 
proliferation of the tumor stem cell population (Zhang et al., 2008). A similar effect has 
been observed in medulloblastoma stem cells, where loss of tumor forming capacity is 
attributed to depletion of cancer stem cells in response to Notch signalling blockade 
(Fan et al., 2006). This data are in agreement with the studies in non-neoplasic stem 
cells that attribute Notch signalling the role of inhibiting neuronal differentiation and 
maintaining the neural progenitor pool (Yoon and Gaiano, 2005). 
 
Neural cancer stem cells as therapeutic targets 
 
Malignant primary brain tumors are characterized by a short median survival 
and almost 100% tumor-related mortality. Therefore, this brain tumor remains one of 
the most lethal forms of human cancer. Glial neoplasms are the most frequent primary 
intracranial neoplasms in man accounting for more than 60% of all primary brain 
tumors. Although glioblastomas, the most malignant of these, rarely spread outside the 
nervous system, they infiltrate crucial structures in the brain, preventing curative 
surgical resection. Radiation and chemotherapy offer only modest benefits and remain 
essentially palliative (Stupp et al., 2005). Conventional chemotherapy and/or radiation 
therapies are not usually designed to target a specific cell subpopulation, and their 
clinical efficacy is measured by their capacity to induce regression of bulk tumor 
lesions. It is therefore difficult to know whether traditional anti-tumor treatments are 
able to target cancer stem cells, which are thought to be resistant to such treatments 
(Guzman et al., 2002; Bao et al., 2006). If glioblastomas are maintained by NCSCs, 
cells that are characterized by low rates of division and proliferation, it is clear that 
therapies such as chemotherapy or radiation, which target actively cycling cells, are 
doubtful to be effective, therefore it is unlikely that existing treatments will ever cure 
most patients with glioblastoma. Thus, the concept of cancer stem cells provides an 
interesting conceptual framework to interpret the phenomenon of tumor relapse as well 
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as the heterogeneity found inside tumors in terms of aberrant cell proliferation and 
differentiation (Reya et al., 2001). Cancer treatment has traditionally been based on the 
implicit assumption that human cancer populations are homogeneous. Cancer is resilient 
to treatment because malignant cells survive chemotherapy and radiation or avoid 
immune surveillance of endogenous cytotoxic T cells and natural killer cells. Since 
cancer stem cells have a capacity for unlimited self-renewal, as well as the ability to 
initiate and drive tumor progression in an animal model (Singh et al., 2004; O'Brien et 
al., 2007) they would seem the most probable candidates responsible for tumor 
chemoresistance and recurrence.  
  
In fact, recent investigations in the field of brain and breast cancers implicate 
cancer stem cells in radiation resistance (Bao et al., 2006; Phillips et al., 2006; 
Woodward et al., 2007). Bao et al. demonstrated that radiation resistance in highly 
malignant gliomas (GBM) is most likely mediated by tumor stem cells (Bao et al., 
2006). This work show that radiation treatment fails in the long run because it cannot 
kill the subpopulation of CD133+ tumor-initiating cells. They showed that CD133+ 
cancer stem cells contributed to glioma resistance through preferential activation of 
DNA damage checkpoint response and an increase in DNA repair capacity compared 
with CD133- tumor cells. The radioresistance of CD133 glioma stem cells could be 
reversed with a specific inhibitor of Chk1 and Chk2 checkpoint kinases, which are 
closely associated with cellular resistance to radiation, thereby providing a therapeutic 
advantage to reducing brain tumor occurrence. As the cell cycle of a normal stem cell is 
tightly controlled by the checkpoint to maintain genomic stability and integrity, the 
defective checkpoint responses associated with early cancer development (Bartkova et 
al., 2005; Gorgoulis et al., 2005) point to an abnormal checkpoint control as a potential 
contributor to the transformation of normal cells into cancer stem cells. Therefore, 
targeting the checkpoint response in CD133+ glioblastoma cells may help to overcome 
the radioresistance of this tumor. Further studies may confirm a rate-limiting role of 
DNA repair for the functionality of glioblastoma cells.  
 
Also, Liu et al demonstrated an increased resistance of CD133-positive brain 
tumor stem cells in response to treatment with chemotherapeutic agents such as 
carboplatin, paclitaxel, and etoposide, compared to CD133-negative cells (Liu et al., 
2006). These studies revealed a higher expression of the multidrug resistance gene 
 9 
BCRP1 and genes that inhibited apoptosis in the CD133-expressing cancer stem cells. 
The work also showed that CD133 expression was significantly higher in recurrent 
glioblastomas compared to their respective newly diagnosed tumors. These results 
suggest that, although chemotherapy kills most of the cells in a tumor, NCSCs remain 
viable and can then reappear due to their enhanced chemoresitance. 
 
Regarding the clinical implications of cancer stem cells, Piccirillo et al. first 
showed that human glioblastoma cells expressed bone morphogenetic proteins (BMPs) 
and their cell surface receptors, BMPs being the soluble factors that normally induce 
neural precursor cells to differentiate into mature astrocytes, a subtype of brain cells 
called glial cells (Piccirillo et al., 2006). These authors showed that BMPs could also 
promote the differentiation of CD133+ brain tumor stem cells, seriously weakening their 
tumor-forming ability. The results further imply that tumor populations at least partially 
retain a developmental hierarchy based on stem cells, and remain able to respond to the 
normal signals that induce them to mature. These findings should lead to renewed 





In conclusion, although major questions remain unanswered concerning the origin and 
function of neural cancer stem cells, their existence in glioblastomas is a widely 
accepted hypothesis. How these NCSC control cell growth and cell-cycle progression of 
glioblastomas, however, is not yet clear. It is not clear whether exists a stem cell-
specific machinery that controls growth and proliferation in a variety of stem cell 
lineages and why does stem cell proliferation get out of control when asymmetric cell 
division is compromised. Furthermore, what are the molecular events that occur when 
such a compromised stem cell becomes unresponsive to growth control signals? The 
striking discovery of stem cell lineages in many tumors, including glioblastomas, might 
lead to the identification of entirely new mechanisms for stem cell control. All the data 
obtained so far suggest that in the coming years, NCSCs will be identified as a powerful 
new potential therapeutic target, and knowledge of the detailed biology and clinical 
significance of this noticeably defined population will provide further support for the 
NCSC hypothesis. Additionally, current efforts focus on the evaluation of target 
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expression profiles in neural cancer stem cells in glioblastomas and on the potential of 
these cells to escape therapy. Ultimately, focusing research efforts on the NCSC may 
drive important advances in our understanding of glioblastoma biology and developing 
potential cures for this devastating disease. 
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